Aptiom generics — when can they launch?
Aptiom (ESLICARBAZEPINE ACETATE) · Sumitomo Pharma Am · 20 active US patents · 8 expired
Where Aptiom sits in the generic timeline
Imminent generic cliff: earliest active US patent for Aptiom expires in 2028 (~2 years from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Formulation — 12 patents
- Method of Use — 8 patents
FDA U-codes carved out by Aptiom patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-2123 | (no description) |
U-2041 | (no description) |
U-2121 | (no description) |
Sample patent estate
Showing 6 of 20 active US patents. View full estate on the Aptiom drug page →
-
This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.USPTO title: Therapeutical uses of eslicarbazepine
-
This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.USPTO title: Therapeutical uses of eslicarbazepine
-
This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.USPTO title: Therapeutical uses of eslicarbazepine
-
This patent protects new therapeutic uses of eslicarbazepine and eslicarbazepine acetate for treating intractable conditions.USPTO title: Therapeutical uses of eslicarbazepine
-
This patent protects a pharmaceutical composition containing licarbazepine acetate, especially eslicarbazepine acetate, in combination with excipients and a granulation process for making it.USPTO title: Pharmaceutical composition comprising licarbazepine acetate
-
This patent protects a pharmaceutical composition containing licarbazepine acetate, especially eslicarbazepine acetate, in combination with excipients and a granulation process for making it.USPTO title: Pharmaceutical composition comprising licarbazepine acetate
Sources
- FDA Orange Book — patents listed against Aptiom (NDA filed 2013)
- Aptiom drug profile — full patent estate, indications, clinical trials, pricing
- Sumitomo Pharma Am patent portfolio
- Patent cliff 2028 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Aptiom — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →